Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

79.82USD
20 May 2019
Change (% chg)

$0.36 (+0.45%)
Prev Close
$79.46
Open
$79.25
Day's High
$80.39
Day's Low
$79.06
Volume
1,066,252
Avg. Vol
1,661,722
52-wk High
$107.24
52-wk Low
$75.64

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.10
Market Cap(Mil.): $117,468.30
Shares Outstanding(Mil.): 1,478.33
Dividend: 1.07
Yield (%): 5.39

Financials

  ABBV.N Industry Sector
P/E (TTM): 22.47 54.03 55.51
EPS (TTM): 3.54 -- --
ROI: 11.45 11.89 11.59
ROE: -- 13.19 16.33

AbbVie halts enrollment after brain cancer trial misses goal, shares fall

AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to meet the main goal in a late-stage trial.

17 May 2019

AbbVie halts enrollment after brain cancer trial misses goal, shares fall

AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to meet the main goal in a late-stage trial.

17 May 2019

UPDATE 1-AbbVie halts enrollment after brain cancer trial misses goal, shares fall

May 17 AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to meet the main goal in a late-stage trial.

17 May 2019

AbbVie halts patient enrollment after brain cancer trial misses goal

May 17 AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to meet the main goal in a late-stage trial.

17 May 2019

UPDATE 2-AbbVie raises profit forecast, but Humira concerns weigh on shares

April 25 AbbVie Inc's better-than-expected quarterly profit and revenue and raised full-year earnings forecast failed to impress investors who focused on the uncertainty around its blockbuster drug Humira as it struggles against cheaper rivals.

25 Apr 2019

AbbVie says Humira rivals from Biogen, Amgen most aggressive so far

April 25 AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.

25 Apr 2019

AbbVie beats estimates as Humira sales fall less than feared

April 25 Drugmaker AbbVie Inc's quarterly revenue beat Wall Street estimates on Thursday, as the decline in sales of its blockbuster rheumatoid arthritis drug Humira was not as steep as expected.

25 Apr 2019

AbbVie's Skyrizi drug to treat psoriasis wins U.S. approval

AbbVie Inc said on Tuesday that the U.S. Food and Drug Administration approved its Skyrizi drug as a treatment for plaque psoriasis at a time when its blockbuster psoriasis drug, Humira, faces patent pressures.

24 Apr 2019

AbbVie's Skyrizi drug to treat psoriasis wins U.S. approval

April 23 AbbVie Inc said on Tuesday that the U.S. Food and Drug Administration approved its Skyrizi drug as a treatment for plaque psoriasis at a time when its blockbuster psoriasis drug, Humira, faces patent pressures.

24 Apr 2019

FDA puts partial hold on clinical trials of AbbVie's cancer drug

AbbVie Inc said on Tuesday the U.S. Food and Drug Administration placed a partial clinical hold on all trials of its cancer drug Venclexta for multiple myeloma, after a review of data found a higher proportion of deaths in the Venclexta arm of the late-stage study.

19 Mar 2019

Earnings vs. Estimates